3AC Stock Overview
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.013 |
| 52 Week High | AU$0.054 |
| 52 Week Low | AU$0.012 |
| Beta | 1.23 |
| 11 Month Change | -7.14% |
| 3 Month Change | 4.00% |
| 1 Year Change | 0% |
| 33 Year Change | -83.75% |
| 5 Year Change | -36.58% |
| Change since IPO | -77.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3AC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.0% | 0.8% | -1.3% |
| 1Y | 0% | -17.5% | 7.4% |
Return vs Industry: 3AC exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: 3AC underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| 3AC volatility | |
|---|---|
| 3AC Average Weekly Movement | 46.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3AC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3AC's weekly volatility has increased from 28% to 47% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| 3AC fundamental statistics | |
|---|---|
| Market cap | €43.92m |
| Earnings (TTM) | -€8.11m |
| Revenue (TTM) | €6.17m |
7.1x
P/S Ratio-5.4x
P/E RatioIs 3AC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3AC income statement (TTM) | |
|---|---|
| Revenue | AU$9.93m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$9.93m |
| Other Expenses | AU$22.98m |
| Earnings | -AU$13.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0044 |
| Gross Margin | 100.00% |
| Net Profit Margin | -131.34% |
| Debt/Equity Ratio | 0% |
How did 3AC perform over the long term?
See historical performance and comparison